From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy.
Department of Bioethics, Warren G. Magnuson Clinical Center & Division of AIDS, National Institute of Allergy & Infectious Diseases, National Institutes of Health (NIH), USA.
Seema
S
Shah
Patricia
P
Zettler
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D032982:Contracts / Q000331:legislation & jurisprudence; D016527:Drug Costs; D011307:Drug Prescriptions / Q000592:standards; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006291:Health Policy / Q000331:legislation & jurisprudence / Q000639:trends; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence; D010344:Patient Advocacy / Q000639:trends; D028701:Patient Rights / Q000331:legislation & jurisprudence / Q000592:standards / Q000639:trends; D035842:Research Subjects; D012449:Safety; D016896:Treatment Outcome; D035501:Uncertainty; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D015507:Drugs, Investigational